| Vol. 11.44 – 12 November, 2020 |
| |
|
|
| The authors demonstrated that the generation of an adaptive immune response from a biomaterial is sufficient to induce cutaneous regenerative healing despite faster scaffold degradation. [Nature Materials] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists found that Netrin G1 (NetG1)+ cancer-associated fibroblasts (CAFs) support pancreatic ductal adenocarcinoma survival, through a NetG1 mediated effect on glutamate/glutamine metabolism. NetG1+ CAFs were intrinsically immunosuppressive and inhibited NK cell mediated killing of tumor cells. [Cancer Discovery] |
|
|
|
| Researchers identified the metalloproteinase inhibitor TIMP1 as a molecular switch that determines the effects of senescence in prostate cancer. Senescence driven either by PTEN deficiency or chemotherapy limited the progression of prostate cancer in mice. [Cancer Cell] |
|
|
|
| Investigators describe the design and synthesis of crystalline supramolecular architectures from charge-complementary heteromeric pairs of collagen-mimetic peptides. [Journal of the American Chemical Society] |
|
|
|
| The authors describe a general strategy for in situ cancer vaccination that exploited both the immunogenic death of tumor cells and dendritic cell recruitment by biomaterial scaffolds. The strategy controled 4T1 tumor growth and reduced metastases with minimal systemic toxicity, potentially providing a potent therapeutic option for triple negative breast cancers. [Nature Communications] |
|
|
|
| In this study, a novel type of injectable hydrogel with dual functions of reactive oxygen species scavenging and O2 generation was fabricated for myocardial infarction treatment, in vivo. [Small] |
|
|
|
| Scientists illustrate the beneficial effect bioactive factors and polyethylene terephthalate incorporation have on anterior cruciate ligament (ACL) regeneration and signal a promising step toward the clinical translation of a functional bioengineered ACL matrix. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Recruitment of myeloid-derived suppressor cells into the tumor microenvironment contributes to cancer immune evasion. Researchers compared the growth and metastasis of melanoma and breast cancer xenografts in mice exhibiting or not exhibiting targeted deletion of Cxcr2 in myeloid cells. [Cancer Immunology Research] |
|
|
|
| Scientists demonstrated that paired related homeobox 1 (Prrx1)-expressing fibroblasts were responsible for acute and chronic fibroses in the ventral dermis. [Cell Reports] |
|
|
|
| High expression of miR-590-3p and low expression of CLCA4 was found in both colorectal cancer (CRC) tissues and cell lines. CLCA4 was indicated as a target gene of miR-590-3p. CAF-derived exosomes were extracted and co-cultured with CRC cells which were then exposed to radiation. [Molecular Therapy-Nucleic Acids] |
|
|
|
| Investigators proposed a practical classifier for the stromal microenvironment to predict the prognosis of esophageal carcinoma patients. [Scientific Reports] |
|
|
|
| To study coordinated cell motility with localized elasticity substrates, scientists fabricated a substrate with localized alternating elasticities to control the mechanical microenvironment of cells. [Scientific Reports] |
|
|
|
| Membrane-type 1 matrix metalloproteinase (MT1-MMP, MMP-14), a transmembrane proteinase with a short cytoplasmic tail, is a major effector of ECM remodeling. The authors provide the first in vivo demonstration that MT1-MMP modulates bone, cartilage and fat homeostasis by controlling skeletal stem cell differentiation through a mechanism independent of proteolysis. [iScience] |
|
|
|
|
| The tumor microenvironment (TME) promotes tumor development via complex intercellular signaling, aiding tumor growth and suppressing immunity. Eph receptors and their ephrin ligands control cell interactions during normal development, and re-emerge in tumors and the TME, where they are implicated in invasion, metastasis and angiogenesis. [Cancer Research] |
|
|
|
| Preclinical knowledge of dysregulated pathways and potential biomarkers for urological cancers has undergone limited translation into the clinic. Moreover, the low approval rate of new anti-cancer drugs and the heterogeneous drug responses in patients indicate that current preclinical models do not always reflect the complexity of malignant disease. [Nature Reviews Urology] |
|
|
|
|
| Spiderwort Inc. has announced that the US FDA has designated CelluBridgeTM, Spiderwort’s Spinal Cord Scaffold Implant, as a “Breakthrough Device”. [Spiderwort Inc.] |
|
|
|
| Surface Oncology develop next-generation immunotherapies that target the tumor microenvironment. They have announced that the US FDA has granted Fast Track designation to SRF388 for the treatment of patients with hepatocellular carcinoma who have been previously treated with standard therapies. [Surface Oncology] |
|
|
|
| Agenus Inc. announced that a milestone payment of $10M from Merck has been triggered with the advancement of an ILT4 antibody, MK-4830, into a Phase II clinical trial. Agenus discovered this novel checkpoint antibody, designed to target immune-suppressive myeloid cells in the tumor microenvironment for the treatment of advanced solid tumors, and licensed the molecule to Merck. [Agenus Inc.] |
|
|
|
|
| January 9 – January 12, 2021 Lake Buena Vista, Florida, United States |
|
|
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| Edward Via College of Osteopathic Medicine – Blacksburg, Virginia, United States |
|
|
|
| Moores Cancer Center, UC San Diego – La Jolla, California, United States |
|
|
|
| H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| Zhejiang University – Zhejiang, China |
|
|
|
|